Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
9.58
+0.25 (2.68%)
Nov 21, 2024, 1:54 PM EST - Market open
Immunome Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immunome stock have an average target of 28.6, with a low estimate of 21 and a high estimate of 35. The average target predicts an increase of 198.54% from the current stock price of 9.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +119.21% | Nov 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $30 | Buy | Initiates | $30 | +213.15% | Nov 8, 2024 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +244.47% | Oct 25, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $27 → $23 | Buy | Maintains | $27 → $23 | +140.08% | Aug 13, 2024 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +244.47% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
8.57M
from 14.02M
Decreased by -38.89%
Revenue Next Year
n/a
from 8.57M
EPS This Year
-4.16
from -5.38
EPS Next Year
-2.96
from -4.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.8M | n/a | 49.4M | ||
| Avg | 8.6M | n/a | 19.7M | ||
| Low | 2.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.8% | - | - | ||
| Avg | -38.9% | - | - | ||
| Low | -79.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.79 | -2.31 | -2.10 | ||
| Avg | -4.16 | -2.96 | -3.17 | ||
| Low | -4.42 | -3.89 | -3.91 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.